Germline mutations in BRCA2 predispose to hereditary breast cancers. BRCA2 protein regulates recombinational repair by interaction with RAD51 via a series of degenerate BRC repeat motifs encoded by exon 11 (BRCA2 996-2113 ), and an unrelated C-terminal domain (BRCA2 ). BRCA2 is also required for meiotic recombination. Here, we show that human BRCA2 binds the meiosis-specific recombinase DMC1 and define the primary DMC1 interaction site to a 26 amino-acid region (BRCA2 ). This region is highly conserved in BRCA2 proteins from a variety of mammalian species, but is absent in BRCA2 from Arabidopsis thaliana, Caenorhabditis elegans, and other eukaryotes. We demonstrate the critical importance of Phe2406, Pro2408, and Pro2409 at the conserved motif 2404 KVFVPPFK 2411 . This interaction domain, defined as the PhePP motif, promotes specific interactions between BRCA2 and DMC1, but not with RAD51. Thus, the RAD51 and DMC1 interaction domains on BRCA2 are distinct from each other, allowing coordinated interactions of the two recombinases with BRCA2 at meiosis. These results lead us to suggest that BRCA2 is a universal regulator of RAD51/DMC1 recombinase actions.
Introduction
The BRCA2 tumour suppressor protein is involved in maintaining the integrity of our genome by its participation in error-free double-strand break (DSB) repair via homologous recombination (HR; Venkitaraman, 2002) . It does so by regulating the actions of RAD51 protein. Recombinases belonging to the RecA/RadA/RAD51 family play a key role in HR by binding to single-stranded DNA generated at the site of a DSB, to form helical nucleoprotein filaments that interact with homologous DNA and promote strand exchange (West, 2003) . BRCA2 and RAD51 interact through a series of eight degenerative motifs within the exon 11 region of BRCA2, which are called the BRC repeats (Bignell et al, 1997; Wong et al, 1997; Chen et al, 1998b) . In addition, there is an unrelated RAD51-binding site located close to the C terminus of BRCA2 (Mizuta et al, 1997; Sharan et al, 1997) , which is regulated in a cell cycle-and DNA damage-dependent manner (Esashi et al, 2005) . In response to DNA damage, RAD51 localises to nuclear foci with BRCA2 (Scully et al, 1997; Sharan et al, 1997; Chen et al, 1998a) , by a mechanism that is BRCA2-dependent (Yuan et al, 1999) . Consistent with a role for BRCA2 in the regulation of HR, BRCA2-deficient cells are defective in DSB repair (Moynahan et al, 2001; Xia et al, 2001) and exhibit spontaneous gross chromosomal rearrangements (Yu et al, 2000) .
HR has a dual cellular function: while it maintains the integrity of DNA in somatic cells, it creates genetic variability by directing DNA exchanges in meiotic cells that result in random combinations of alleles and traits. BRCA2 appears to play an important role in meiotic recombination in mammalian cells, as it is highly expressed during spermatogenesis in mice (Connor et al, 1997) , and localises to meiotic chromosomes during early prophase I when homologous chromosomes undergo pairing (Chen et al, 1998a) . Although targeted disruption of the BRCA2 gene in mouse leads to embryonic lethality (Ludwig et al, 1997; Sharan et al, 1997; Suzuki et al, 1997) , an analysis of the role of BRCA2 in meiosis has been made possible through the generation of a viable Brca2 null mouse carrying a bacterial artificial chromosome containing the human BRCA2 gene (Sharan et al, 2004) . These mice, which exhibit low levels of expression of human BRCA2 protein in the gonads, are infertile because spermatocytes fail to progress beyond the early prophase I stage of meiosis. A role for BRCA2 in meiotic recombination has also been demonstrated in Arabidopsis thaliana where siRNA against BRCA2 leads to meiotic defects and partial sterility (Siaud et al, 2004) .
In addition to RAD51, meiotic recombination requires the functions of DMC1, a meiosis-specific paralog of RAD51 (Bishop et al, 1992; Yoshida et al, 1998) . Like RAD51, recombinant human DMC1 protein forms octameric rings that are capable of binding DNA and forming helical nucleoprotein filaments that catalyse strand exchange Passy et al, 1999; Kinebuchi et al, 2004; Sehorn et al, 2004; Bugreev et al, 2005) . The two recombinases colocalise to nuclear foci during meiotic recombination (Bishop, 1994; Chen et al, 1998a; Tarsounas et al, 1999) . Consistent with these observations, mouse Dmc1 knockouts are infertile due to defects in chromosome synapsis during meiotic recombination (Pittman et al, 1998; Yoshida et al, 1998) . However, it is not known how these two recombinases function during meiosis, whether they play independent roles or act in concert, or how their activities are regulated and coordinated.
A potential role for BRCA2 in coordinating the activities of RAD51 and DMC1 was implied by studies showing that meiotic chromosomes from mouse spermatocytes exhibiting impaired expression of BRCA2 had reduced numbers of RAD51 and DMC1 foci (Sharan et al, 2004) . Also, in plants the AtBRCA2 protein has been shown to interact with AtDMC1, an interaction mediated by one of the four BRC repeats (BRC2) found in AtBRCA2 (Siaud et al, 2004; Dray et al, 2006) . To date, however, there is no information relating to interactions between mammalian BRCA2 and DMC1 proteins.
In this study, we define the interactions between human BRCA2 and DMC1. Surprisingly, we found that the primary DMC1 interaction domain of BRCA2 maps to a region of BRCA2 that is distinct from the BRC repeats that facilitate interactions with RAD51. These results provide the first insight into understanding the coordinating role that BRCA2 provides in mammalian meiotic recombination.
Results

In vivo interactions of BRCA2 with DMC1
The interaction of human BRCA2 and DMC1 in vivo was investigated by using rabbit polyclonal antibodies to immunoprecipitate BRCA2 complexes from extracts prepared from human 293T cells transiently expressing Myc-tagged DMC1. The BRCA2 pull-downs were analysed by Western blotting using mouse monoclonal antibodies specific for BRCA2 ( Figure 1 , top panel), Myc-DMC1 (middle panel), and RAD51 (lower panel). We found that the BRCA2-specific antibodies pulled down both DMC1 and RAD51 (lane f), whereas IgG control reactions failed to pull down either of these proteins (lane e). Control reactions, using extracts from mock-transfected 293T cells, rather than Myc-DMC1-transfected 293T cells, showed the absence of DMC1 from the BRCA2-RAD51 immunoprecipitates, as expected since DMC1 is not normally expressed in somatic cells (lane d). Interestingly, the amounts of endogenous RAD51 present in the BRCA2 immunoprecipitates from Myc-DMC1 or mocktransfected cells were similar, indicating that while DMC1 can interact with BRCA2 in vivo, its overexpression does not significantly affect the binding of RAD51 to BRCA2.
Mapping the DMC1 interaction sites in BRCA2
Studies of the interaction between BRCA2 and DMC1 in A. thaliana indicate that DMC1, like RAD51, interacts with BRCA2 through the BRC repeat sequences (Dray et al, 2006) . To map the interaction domains between the human BRCA2 and DMC1 proteins, we used a series of nine overlapping glutathione S-transferase (GST) fusion proteins, designated B2-1 to B2-9 (Lee et al, 2004) , that span the entire coding region of BRCA2 (Figure 2A ). Lysates from Escherichia coli expressing each of the nine GST fusion proteins ( Figure 2B , lanes b-j), and GST alone (lane a), were incubated with glutathione beads, and purified recombinant human DMC1 or RAD51. Complexes bound to the beads were analysed by Western blotting for either DMC1 ( Figure 2B , top panel) or RAD51 ( Figure 2B , middle panel). Similar amounts of GST-tagged BRCA2 fragments were observed in each pull-down ( Figure 2B , bottom panel). As reported previously (Esashi et al, 2005) , RAD51 interacted specifically with B2-3 (lane d) and B2-4 (lane e), the fragments containing BRC repeats 1-5, and with B2-9 (lane j), which corresponds to the C-terminal region of BRCA2. In the case of DMC1, however, we failed to observe interactions between DMC1 and any of the BRCA2 GST fragments containing BRC repeats ( Figure 2B , top panel, lanes d-f). Instead, we found that DMC1 interacted specifically with B2-6 (lane g) and with the C-terminal region B2-9 (lane j).
A region of BRCA2 that interacts with DMC1 but not RAD51 Presently, there is very little information relating to the function of the region of BRCA2 defined by B2-6 (amino acids 2106-2472). To map the DMC1 interaction domain in greater detail, we subdivided the region into a series of smaller GST fusion proteins, depicted in Figure 3A , designated B2-6.1 to B2-6.5. These fusion proteins were then expressed and used in DMC1 pull-down assays ( Figure 3B ). We found that DMC1 interacted strongly with B2-6.5 ( Figure 3B , lane g), corresponding to BRCA2 2340-2472 , but did not interact with any of the other fusion proteins (lanes c-f).
To ensure that the B2-6.5 region of BRCA2 interacts specifically with DMC1, competition experiments were carried out between RAD51 and DMC1 for binding to B2-6.5. We found that a 10-fold excess of purified RAD51 had no effect on the interaction between DMC1 and B2-6.5 ( Figure 3C , compare lanes a-d). In these reactions, RAD51 could not be detected in the B2-6.5 pull-down by Western blotting (data not shown). These experiments indicate that there are no direct interactions between the two recombinases and show that BRCA2 2340-2472 contains a novel domain that binds specifically to DMC1 but does not interact with RAD51.
The interaction of this novel BRCA2 domain with DMC1 was confirmed by yeast two-hybrid analysis, a system used previously to evaluate BRCA2-RAD51 interactions (Wong et al, 1997; Chen et al, 1998b) . It was also the primary method used to map interactions between a BRC repeat of AtBRCA2 and AtDMC1 (Dray et al, 2006) . For the yeast two-hybrid analysis, DMC1 and RAD51 were fused to the GAL4 activation domain, while a variety of BRCA2 fragments were fused to the GAL4 DNA-binding domain. We used the eight BRC repeats, B2-6 and B2-6.5 (both identified in the above GST pull-down experiments to interact specifically with DMC1), and the C-terminal BRCA2 fragments B2-9 and TR2 (previously shown to be the C-terminal RAD51 interaction domain (Esashi et al, 2005) ). We also expressed a large BRCA2 fragment, BRCA2 , which contains all eight BRC repeats. We found that BRCA2-DMC1 interactions were observed with the two constructs containing the newly identified DMC1 interaction domain BRCA2 ( Figure 4 , B2-6.5 and B2-6). Neither of these BRCA2 fragments resulted in growth when combined with RAD51. These results confirm the finding that BRCA2 2340-2472 contains a domain that interacts specifically with DMC1.
As expected, RAD51 was found to interact with the C-terminal part of BRCA2, several of the individual BRC repeats, and with the BRCA2 996-2113 fragment containing all BRC repeats. In the two-hybrid assay, we also observed an interaction between DMC1 and BRC repeat 4 (BRC4), but this interaction was relatively weak in comparison with those of B2-6 or B2-6.5, as indicated by the lack of growth in the absence of uracil (ÀLTU). Importantly, growth was not observed when DMC1 was expressed with BRCA2 , which contains all eight BRC repeats. The weakness of the BRC4-DMC1 interaction, coupled with the absence of similar interactions in the GST pull-down experiments, may question the physiological relevance of this interaction.
Interactions of RAD51 and DMC1 with the C-terminal region of BRCA2
The two-hybrid analysis confirmed interactions between the C-terminal region of BRCA2 (TR2 and B2-9) with RAD51, but failed to support the pull-down experiments indicating an interaction of this region with DMC1. Further experiments were therefore carried out to establish that both RAD51 and DMC1 could interact with this domain of BRCA2. First, we used three small GST-tagged BRCA2 fragments, TR1, TR2, and TR3 ( Figure 5A ), to map the interaction of DMC1 with the C-terminal region of BRCA2 in greater detail. GST pull-downs showed that both DMC1 and RAD51 bind to the TR2 fusion protein (BRCA2 3265-3330 ), but not to either TR1 (BRCA2 3189-3274 ) or TR3 (BRCA2 3325-3418 ) ( Figure 5B ). Next, we carried out competition experiments to determine which of the two proteins exhibited the highest binding affinity for this site in BRCA2. For this analysis, TR2 bound to glutathione beads was mixed with constant amounts of DMC1 and increasing amounts of RAD51 and, after extensive washing, the complexes bound to beads were analysed by Western blotting. We found that the presence of RAD51, even at submolar concentrations compared with DMC1, efficiently competed away the binding of DMC1 to the TR2 region of BRCA2 ( Figure 5C, lanes a-d) . In contrast, DMC1 failed to compete with RAD51 for interaction with TR2 (lanes e-h). These results indicate that the DMC1-TR2 interaction is relatively weak compared to RAD51-TR2 complex formation, helping to explain why these interactions were not seen in the yeast two-hybrid studies. Previously, it was shown that CDK-dependent phosphorylation of serine 3291 in the TR2 region of BRCA2 inhibits RAD51 interaction with this site and that this modification may serve as a regulatory mechanism for recombinational repair (Esashi et al, 2005) . We therefore investigated the effect of TR2 phosphorylation on the binding of DMC1 to this region. Using biotinylated TR2 peptides phosphorylated at S3291, or a series of other control sites ( Figure 5D ), we found that peptides containing phosphorylated S3291 failed to bind RAD51 but were capable of interacting normally with -LTH + 25 mM 3-AT -LTH + 100 mM 3-AT - LTU  -LT   DMC1  DMC1  DMC1  DMC1  RAD51  RAD51  RAD51  RAD51   BRC1  BRC2  BRC3  BRC4  BRC5  BRC6  BRC7  BRC8 B2-6.5 TR2 B2-6 B2-9 BRCA2 996-2113 Figure 4 Yeast two-hybrid analysis of interactions between DMC1 or RAD51 and a series of BRCA2 fragments. Two-hybrid analysis was carried out as described in Methods, and diluted cells were plated on permissive ÀLeu/ÀTrp plates (ÀLT), or selection plates: ÀLeu/ÀTrp/ÀHis þ 25 mM 3-AT (ÀLTH þ 25 mM 3-AT); ÀLeu/ÀTrp/ÀHis þ 100 mM 3-AT (ÀLTH þ 100 mM 3-AT); or ÀLeu/ÀTrp/ÀUra (ÀLTU Figure 5E, lanes c, e and f) . These results were confirmed by competition studies in which biotinylated peptides corresponding to TR2, unphosphorylated, or phosphorylated at S3291, were incubated with DMC1 in the presence of increasing amounts of RAD51. As observed with TR2, we found that RAD51 could easily compete for DMC1 binding to TR2 ( Figure 5F , lanes a-d), whereas it failed as a competitor with S3291-phosphorylated TR2 (lanes e-h). Thus, the phosphorylation of S3291 can modulate interactions with RAD51, but not DMC1, and may provide a mechanism for the differential regulation of BRCA2-RAD51 and BRCA2-DMC1 interactions.
Identification of a conserved domain in BRCA2, essential for DMC1 interaction
Since yeast two-hybrid and GST pull-down analyses had both confirmed the presence of a specific DMC1 interacting region in B2-6.5. (BRCA2 2340-2472 ), we wished to define this domain in greater detail. First, we generated four overlapping biotinylated synthetic peptides covering the region ( Figure 6A , IR1-IR4), and used them in streptavidin pull-down experiments to show that the DMC1 interaction domain was contained within IR2 (BRCA2 2350-2417 ) and IR3 (BRCA2 2371-2438 ) ( Figure 6B ). Second, to narrow down this interaction domain even further, we synthesised a 30-mer peptide array that covered the entire BRCA2 2350-2417 region. On this membrane, which was subsequently probed with DMC1, each peptide overlapped the next by 29 amino acids, leading to a change of just one amino acid per peptide. We found that DMC1 interacted strongly with six to seven consecutive peptides, all containing the region corresponding to BRCA2 ( Figure 6C , lower panel). This region is highly conserved in mammalian BRCA2 from a variety of species ( Figure 6D) , and is also found in chicken BRCA2. In contrast, the region has diverged in the BRCA2 homologues found in A. thaliana, Caenorhabditis elegans, Ustilago maydis, and Trypanosoma cruzi. Finally, to define precisely which amino acids are essential for the BRCA2-DMC1 interaction, we generated a mutant peptide array of 30-mer peptides containing the conserved region of BRCA2 important for DMC1 interaction. In this array, the 30 amino acids corresponding to BRCA2 were sequentially substituted (one at a time) by the 20 common amino acids (each substitute is indicated at the right of the membrane in Figure 6E ). Hence, on this membrane, the first phenylalanine (F2382) is substituted in the first column, in the second column the tyrosine (Y2383) has been substituted, and so on. When this membrane was probed for DMC1 interaction, we observed that substitution of Phe2406 with any amino acid, except the two other aromatic amino acids, abolished interaction with DMC1. Similarly, substitution of Pro2408 or Pro2409 led to a loss of interaction with DMC1. All three amino acids were found to be located in the highly conserved 2404 KVFVPPFK 2411 region of BRCA2.
Discussion
In this work, we have demonstrated that human BRCA2 is capable of binding the meiosis-specific recombinase DMC1 via two different binding sites. The first is located at the C terminus of BRCA2 and corresponds to the region also bound by RAD51 protein. The second, however, represents the primary DMC1 interaction domain located within the relatively uncharacterised central part of BRCA2, contained within B2-6. Using yeast two-hybrid assays, pull-down experiments, and peptide arrays, we defined this interaction domain to the region corresponding to BRCA2 . Within this region, we showed the critical importance of B2-6.5 2340  2472  IR1  IR2  IR3  IR4   IR1  IR2  IR3  IR4  TR2   DMC1 Peptides Phe2406, Pro2408, and Pro2409 located in the conserved motif KVFVPPFK, and for simplicity will refer to this DMC1 interaction domain as the PhePP motif. The PhePP motif of BRCA2 interacts specifically with DMC1, and not with RAD51. The importance of the region is indicated by its conservation in different mammalian species and in chicken BRCA2. This DMC1 interaction domain, however, is divergent in BRCA2 homologues from other eukaryotes such as A. thaliana and C. elegans. When our studies were initiated, we were surprised to identify this novel interaction domain, as it was known that AtBRCA2 and AtDMC1 can interact through one of the four degenerate plant BRC repeats (Dray et al, 2006) . However, modelling studies based on the crystal structure of a RAD51-BRC4 fusion protein suggest that DMC1 has polar or charged residues at the hydrophobic RAD51-binding patch for BRC4, which is likely to preclude its interaction with this BRC repeat (Pellegrini et al, 2002; Lo et al, 2003) . It might also be significant that the AtBRCA2 proteins (there are two AtBRCA2 isoforms at 1151 or 1155 amino acids) are considerably shorter than the human counterpart (3418 amino acids), such that two of the plant BRC repeats (BRC4 and BRC2, respectively) have evolved independently to interact with either RAD51 or DMC1 (Dray et al, 2006) . It remains to be established whether the diverged PhePP motif in A. thaliana can interact with AtDMC1. The divergence of the PhePP domain in C. elegans is less surprising given the absence of DMC1 in this organism, which promotes meiotic recombination through the high-level expression of RAD51 alone (Takanami et al, 2000) .
In addition to the specific DMC1 interaction domain in BRCA2, we found that DMC1, like RAD51, could interact with the C-terminal region of BRCA2 known as TR2 (BRCA2 ). In comparison to the RAD51-TR2 interaction, the association of DMC1 with TR2 appears to be relatively weak, and it was found that RAD51 could easily compete with DMC1 for the C-terminal interaction site. However, it is known that interactions between RAD51 and the C terminus of BRCA2 are blocked by S3291 phosphorylation, a modification event that has little or no impact upon DMC1 binding. Thus, circumstances might exist that would favour DMC1, rather than RAD51, interaction with the BRCA2 C terminus. Our attempts to demonstrate phosphorylation of S3291 during meiotic recombination, which might favour interactions with DMC1 have so far proven to be unsuccessful, so the relevance of this potential binding switch upon phosphorylation is presently unknown. However, the lack of meiotic defects in mice harbouring deletions of the BRCA2 C terminus may well indicate that interactions between the BRCA2 C-terminal region and RAD51/DMC1 may not be so critical for the functions of BRCA2 during meiotic recombination (Atanassov et al, 2005) .
The precise role played by BRCA2 in regulating homologous recombinational repair of DNA DSBs has yet to be fully defined. However, we are now beginning to understand the key role played by this protein in binding RAD51 and facilitating its relocalisation in somatic cells in response to DNA breaks. A similar situation exists in meiotic cells, as RAD51 and DMC1 colocalise to Spo11-induced DSBs during meiotic recombination (Bishop, 1994; Tarsounas et al, 1999) . Our observations of a novel DMC1 interaction site at BRCA2 2386-2411 , located away from the BRC repeats that mediate the primary interactions with RAD51, lead us to speculate that BRCA2 is capable of coordinately binding RAD51 and DMC1 to form a BRCA2-RAD51-DMC1 complex, which may facilitate the localisation of both recombinases to DNA break sites at the initiation of meiotic recombination. There, as in mitotic cells, it is likely that BRCA2 may participate in nucleoprotein filament formation leading to subsequent repair.
Materials and methods
Plasmids
The GST-tagged BRCA2 constructs B2-1 to B2-9 (Lee et al, 2004) and TR1-TR3 (Esashi et al, 2005) have been described previously. The GST-tagged BRCA2 constructs B2-6.1 to B2-6.5 were cloned into the SalI/NotI sites of pGEX-4T3 (Amersham) using PCR amplification. The mammalian expression vector pMyc-DMC1 was created by PCR amplification and subsequent insertion of the DMC1 sequence at the BamHI/SalI sites in the pCMV-Tag3 vector (Stratagene). The yeast two-hybrid plasmids were all cloned by PCR into the Gateway pDONR221 vector (Invitrogen) and subsequently transferred into pDEST22 (RAD51 and DMC1), or pDEST32 (all the BRCA2 constructs) (Invitrogen). All PCR-amplified sequences were verified by sequencing.
Proteins and peptides
Recombinant His 10 -DMC1 and RAD51 were prepared as described (Baumann et al, 1997; Masson et al, 1999) . Peptides were made by solid-phase synthesis and purified by high-performance liquid chromatography, and their sequences were verified by mass spectroscopy. All peptides contained an N-terminal biotin group with an aminohexanoic spacer. GST-tagged BRCA2 constructs were expressed in E. coli strain BL21 RIL codon plus (Stratagene) by IPTG induction (0.1 mM) for 2 h at 181C.
In vivo protein interactions
Human 293T cells were cultured in E4 medium supplemented with 10% FBS and antibiotics. Transfection with pMyc-DMC1 was performed using Fugene 6 (Roche) according to the manufacturer's instructions. Twenty-four hours post-transfection, cell were collected and lysed using a modified RIPA buffer (50 mM Tris-HCl, pH 7.5, 0.2% NP-40, 0.1% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF, and Complete Protease Inhibitor Cocktail (Roche)). The lysates were added to 20 ml protein A magnetic beads (Invitrogen), which had been preincubated with 20 mg nonspecific rabbit IgG (Santa Cruz Biotechnology) or anti-BRCA2 rabbit polyclonal antibodies (Ab-2, Calbiochem) in RIPA buffer containing 2 mg/ml BSA. After incubation at 41C, the beads were washed extensively, boiled in SDS loading buffer, and the precipitates analysed by Western blotting using either BRCA2 mouse monoclonal antibodies (Ab-1, Calbiochem), c-Myc mouse monoclonal antibodies (9E10, CRUK), or RAD51 monoclonal antibodies (14B4, Abcam).
In vitro GST pull-downs E. coli cells expressing BRCA2 fragments were lysed in IP buffer (50 mM Tris-HCl, pH 7.5, 250 mM KCl, 5% glycerol, 0.5% NP-40, 2 mM EDTA, 1 mM DTT, 1 mM Pefabloc SC, Complete Protease Inhibitor Cocktail (Roche), and 25 U/ml Benzonase Nuclease). Saturating amounts of lysates were mixed with 15 ml glutathione Sepharose 4B beads (Amersham), and incubated with 200 ng DMC1 or RAD51 in IP buffer containing 2 mg/ml BSA. After incubation and extensive washing with IP buffer, the precipitates were analysed by Western blotting using HRP-conjugated GST mouse monoclonal antibodies (B14, Santa Cruz Biotechnology), 6 Â His mouse monoclonal antibodies (Clontech) for detection of DMC1, and RAD51 monoclonal antibodies (14B4, Abcam). For DMC1/RAD51 competition, the procedure was as above, adding 200 ng DMC1 or RAD51 alone or in combination with the designated amounts of competitor.
In vitro peptide interaction studies
Biotinylated peptides (300 ng) were mixed with 6 ml magnetic Streptavidin Beads (Invitrogen) in IP buffer containing 2 mg/ml BSA and washed, before addition of 60 ng DMC1 or RAD51 in IP buffer containing 2 mg/ml BSA. After incubation and extensive washing with IP buffer, the precipitates were analysed by Western blotting using HRP-conjugated Streptavidin for detection of the biotinylated peptides (Abcam), 6 Â His mouse monoclonal antibodies (Clontech) for detection of DMC1, and RAD51 monoclonal antibodies (14B4, Abcam). For DMC1/RAD51 competition experiments, the procedure was similar to that described except that the reactions contain 60 ng DMC1 alone or in combination with the designated amounts of RAD51.
Peptide arrays
For the peptide array studies, peptides were synthesised and spotted onto cellulose membranes. The membrane used in Figure 6C contained peptides, 30 amino acids in length, corresponding to BRCA2 . The first peptide in this array corresponds to BRCA2 , the next to BRCA2 , the third to BRCA2 , and so on. The membrane was activated in 50% methanol before blocking in 5% milk in TBS þ 0.1% Tween 20 (TBS-T). The membrane was then incubated with His-tagged DMC1 in 5% milk in TBS-T overnight, and bound DMC1 was detected by incubation with anti-His monoclonal antibodies and chemiluminescence. Subsequently, the membrane was stained with Ponceau, to reveal the exact location of each peptide. The mutant peptide array in Figure 6E was generated by synthesising 600 peptides corresponding to BRCA2 , where each peptide sequentially had one of the amino acids substituted with each of the 20 common amino acids. The membrane was organised so that each of the 30 columns had the same amino acids in the 30-mer substituted. Each of the 20 rows on the membrane contains the identical amino-acid substitution.
Yeast two-hybrid assays
The ProQuest Two-Hybrid System (Invitrogen) was used for the analysis according to the manufacturer's instructions. DMC1 and RAD51 were fused to the GAL4 activation domain, while the BRCA2 fragments were fused to the GAL4 DNA-binding domain. After transforming the MaV203 strain with the different combinations of constructs by the lithium-acetate method, colonies were picked and grown in SD-medium minus Leu and Trp (Clontech) to stationary phase. The cells were then diluted and 10 000, 1000, or 100 cells, respectively, were plated onto selective plates, which were subsequently incubated at 301C for 3 days. Interactions were assessed by analysing transcription of two different reporter genes, URA3 and HIS3, which resulted in grown on agar plates lacking uracil and histidine, respectively. Furthermore, on plates lacking histidine, two different concentrations of the HIS3 inhibitor 3-Amino-1,2,4-triazole (3-AT) was used, resulting in different stringency of these plates. Control experiments showed that growth was not observed on selective plates when the cells were transfected either with the GAL4 activation-or with DNA bindingdomains.
